Login
Navigate Fool.com
Will JAZZ beat
the market?
Community Rating: 3 Stars: Appealing

142.44 -1.48 (-1.02%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $146.21
Previous Close $143.91
Daily Range $139.67 - $146.39
52-Week Range $53.29 - $176.60
Market Cap $8.3B
P/E Ratio 41.00
Dividend (Yield) $0.00 (0.0%)
Volume 600,380
Average Daily Volume 1,258,510
Current FY EPS $7.56

How do you think JAZZ
will perform against the market?

Top JAZZ Bull/Bear Pitches

 

TMFUltraLong (< 20)
Submitted June 9, 2011

It's no secret that the technicals are a bloody mess, but based on the fundamentals alone this company looks like a very probably double. I'm basing this on the fact that Xyrem has been growing consid … More

2 Replies Reply Report this Post
 

ross812 (< 20)
Submitted March 5, 2010

Garbage. Garbage. Garbage!!! See what happens if they fail a drug trial!

0 Replies Reply Report this Post

News & Commentary

3 Stocks to Get on Your Watchlist

Jazz Pharmaceuticals, General Electric, and Sears Holdings are this week's must-watch stocks.

This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value

Instead of sitting back and waiting to be purchased, AstraZeneca could bolster shareholder value by going on the offensive.

How Are Orphan Drugmakers Faring in the Great Biotech Downturn?

Orphan drugmakers led the biotech rally upward. Is it now leading it downward?

Notable ETF Outflow Detected - VBK, ARCP, JAZZ, WAB

3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely

Rumors continue to swirl that Ariad is a takeover target, but these three factors could eliminate any chance of that happening.

Is an Ariad Pharmaceuticals, Inc. Acquisition Realistic?

Jazz Pharmaceuticals, GlaxoSmithKline, and Eli Lilly have all been linked to Ariad Pharmaceuticals as potential acquirers, but will it actually occur?

Biotechs Giving Uncle Sam the Shaft

Horizon Pharma, Actavis, Alkermes, and Perrigo have all purchased companies in part to move out of the U.S. and lower their tax rates. The strategy could make companies such as Jazz Pharmaceuticals a takeout target.

From Marijuana to Snake Venom: 9 Drugs Derived from Unlikely Sources

Cannabis plants, snake venom, and snail venom are just some of the interesting sources drug developers have used to create these nine drugs.

VBK, ARCP, JAZZ, WAB: Large Outflows Detected at ETF

Wall Street Positive On Hopes For Global Stimulus

See More JAZZ News...

Sector

Healthcare

Industry

Drugs

Jazz Pharmaceuticals, Inc. (JAZZ) Description

A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Website: http://www.jazzpharma.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks